title: Passive immunotherapy for Alzheimer's disease: what have we learned, and where are we headed?
authors.forename: P S
authors.initials: PS
authors.lastname: Aisen
authors.forename: B
authors.initials: B
authors.lastname: Vellas
mesh_terms: D000544:Alzheimer Disease / Q000276:immunology* / Q000517:prevention & control*; D000682:Amyloid / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology; D004195:Disease Models, Animal; D006801:Humans; D007116:Immunization, Passive / Q000379:methods*; D051379:Mice
chemical_list: D000682:Amyloid; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C571128:gantenerumab; C550616:solanezumab; C545458:bapineuzumab; C573372:crenezumab